Schonfeld Strategic Advisors’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-3,860
Closed -$559K 2197
2024
Q1
$559K Buy
+3,860
New +$326K ﹤0.01% 1441
2023
Q1
Sell
-4,530
Closed -$262K 2149
2022
Q4
$262K Sell
4,530
-1,580
-26% -$97.6K ﹤0.01% 1860
2022
Q3
$574K Buy
6,110
+4,460
+270% +$635K ﹤0.01% 1656
2022
Q2
$368K Buy
+1,650
New +$553K ﹤0.01% 1539
2021
Q2
Sell
-1,650
Closed -$1.81M 1976
2021
Q1
$1.81M Sell
1,650
-397
-19% -$524K 0.02% 695
2020
Q4
$2.92M Buy
2,047
+1,345
+192% +$1.43M 0.04% 520
2020
Q3
$495K Buy
+702
New +$510K 0.01% 916
2020
Q2
Sell
-640
Closed -$224K 1270
2020
Q1
$224K Sell
640
-224
-26% -$159K 0.01% 868
2019
Q4
$543K Buy
+864
New +$422K 0.01% 714
2019
Q2
Sell
-5,350
Closed -$885K 1018
2019
Q1
$885K Sell
5,350
-2,460
-31% -$400K 0.03% 535
2018
Q4
$846K Buy
7,810
+1,820
+30% +$307K 0.03% 517
2018
Q3
$1.5M Buy
+5,990
New +$1.29M 0.07% 344

Other funds holding CDLX

Schonfeld Strategic Advisors's CDLX Position: Q2 2024 in Review

Schonfeld Strategic Advisors sold out of Cardlytics (CDLX) in Q2 2024, closing a stake of 3,860 shares — an estimated $559K sold.

Schonfeld Strategic Advisors first reported a position in CDLX in Q3 2018 and held it in 12 quarters. The position peaked at $2.92M in Q4 2020. 127 funds tracked by Wall St. Rank hold CDLX as of Q2 2024.

  • Schonfeld Strategic Advisors reported no remaining Cardlytics position as of Q2 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 3,860 Cardlytics shares in Q2 2024, an estimated $559K.
  • Schonfeld Strategic Advisors first reported a position in Cardlytics in Q3 2018 and held it in 12 quarters.
  • Schonfeld Strategic Advisors's Cardlytics position peaked at $2.92M in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Cardlytics as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.